

# Status of Development Pipeline (As of July 24, 2020)

## Main Status of Development Pipelines (Oncology)

Product Name or Development Code (Generic Name)	Mechanism of Action, etc.	Target Disease	Development Stage				Area	In-house / In-license
			I	II	III	Filed		
OPDIVO Intravenous Infusion (Nivolumab)	Anti-PD-1 antibody	Gastro-esophageal junction cancer and esophageal cancer					JP-KR-TW	In-house (Co-development with Bristol-Myers Squibb)
		Small cell lung cancer					JP-KR-TW	
		Hepatocellular carcinoma					JP-KR	
		Glioblastoma					JP	
		Urothelial carcinoma					JP	
		Ovarian cancer					JP-KR-TW	
		Bladder cancer					JP-KR-TW	
		Prostate cancer					JP-KR-TW	
		Solid tumors (Cervix carcinoma, Uterine body cancer, Soft tissue sarcoma)					JP	
		Central nervous system lymphoma, Primary testicular lymphoma					JP	
		Pancreatic cancer					JP-KR-TW	
		Biliary tract cancer					JP	
		Virus positive / negative solid carcinoma					JP-KR-TW	
VELEXBRU Tablet (Tirabrutinib)	Bruton's tyrosine kinase (BTK) inhibitor	Primary macroglobulinemia, Lymphoplasmacytic lymphoma					JP	In-house
YERVOY Injection* (Ipilimumab)	Anti-CTLA-4 antibody	Colorectal cancer (MSI-H)					JP	Co-development with Bristol-Myers Squibb
		Non-small cell lung cancer					JP	
							KR-TW	
		Small cell lung cancer					JP-KR-TW	
		Head and neck cancer					JP-KR-TW	
		Gastric cancer					JP-KR-TW	
		Malignant pleural mesothelioma					JP	
		Esophageal cancer					JP-KR-TW	
		Urothelial carcinoma					JP-KR-TW	
		Hepatocellular carcinoma					JP-KR-TW	
		Virus positive / negative solid carcinoma					JP-KR-TW	
ONO-7643 (Anamorelin)	Ghrelin mimetic	Cancer cachexia					JP	Helsinn Healthcare
BRAFTOVI Capsule (Encorafenib)	BRAF inhibitor	Colorectal cancer					JP	Pfizer
							KR	
		Melanoma					KR	
MEKTOVI Tablet (Binimetinib)	MEK inhibitor	Colorectal cancer					JP	Pfizer
							KR	
		Melanoma					KR	

Product Name or Development Code (Generic Name)	Mechanism of Action, etc.	Target Disease	Development Stage				Area	In-house / In-license
			I	II	III	Filed		
ONO-7701* (Linrodostat)	IDO1 inhibitor	Bladder cancer					JP·KR·TW	Co-development with Bristol-Myers Squibb
ONO-7912 (Devimistat)	Cancer metabolism inhibitor	Pancreatic cancer					KR	Rafael Pharmaceuticals
		Acute myeloid leukemia					KR	
ONO-4687* (Cabiralizumab)	Anti-CSF-1R antibody	Pancreatic cancer					JP·KR·TW	Co-development with Bristol-Myers Squibb
ONO-4686*	Anti-TIGIT antibody	Solid tumor					JP	Co-development with Bristol-Myers Squibb
ONO-4482* (Relatlimab)	Anti-LAG-3 antibody	Melanoma					JP	Co-development with Bristol-Myers Squibb
ONO-7807*	Anti-TIM-3 antibody	Solid tumor					JP	Co-development with Bristol-Myers Squibb
ONO-4578*	PG receptor (EP4) antagonist	Solid tumor					JP	In-house
ONO-4483* (Lirilumab)	Anti-KIR antibody	Solid tumor					JP	Co-development with Bristol-Myers Squibb
ONO-7475	Axl / Mer inhibitor	Solid tumor*					JP	In-house
		Acute leukemia					US	
ONO-7911* (Bempegaldesleukin)	PEGylated IL-2	Solid tumor					JP	Co-development with Bristol-Myers Squibb
ONO-7913 (Magrolimab)	Anti-CD47 antibody	Solid tumor					JP	Gilead Sciences

★ : Combination with OPDIVO

## Main Status of Development Pipelines (Other than Oncology)

Product Name or Development Code (Generic Name)	Mechanism of Action, etc.	Target Disease	Development Stage				Area	In-house / In-license
			I	II	III	Filed		
ONO-5704 / SI-613	Hyaluronic acid-NSAID	Osteoarthritis					JP	Seikagaku
		Enthesopathy					JP	
ORENCIA SC (Abatacept)	T-cell activation inhibitor	Polymyositis / Dermatomyositis					JP	Co-development with Bristol-Myers Squibb
ONOACT for Intravenous Infusion (Landiolol hydrochloride)	Short-acting selective $\beta_1$ blocker	Tachyarrhythmia in low cardiac function for pediatric use					JP	In-house
VELEXBRU Tablet (Tirabrutinib)	Bruton's tyrosine kinase (BTK) inhibitor	Pemphigus					JP	In-house
ONO-7269	FXIa inhibitor	Cerebral infarction					JP	In-house
ONO-4685	PD-1×CD3 Bispecific antibody	Autoimmune disease					JP	In-house
ONO-2808	S1P5 receptor agonist	Neurodegenerative disease					EU	In-house
ONO-7684	FXIa inhibitor	Thrombosis					EU	In-house
ONO-2910	Schwann cell differentiation promoter	Peripheral neuropathy					JP	In-house
FOIPAN Tablet (Camostat mesilate)	Protease enzyme inhibitor	Novel coronavirus infectious disease (COVID-19)					JP	In-house